Company: PSTV
Filing Date: 2025-04-04
Form Type: S-3
Source: 0001193125-25-073481
Chunk: 10

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-04
Form: S-3
Chunk 10
---
 shares of common stock, (ii) 19,650,000 shares of common stock issuable upon exercise of Pre-Funded Warrants,                                                          
 (iii) 280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock Warrants, (iv) 1,261,896,210 shares of common stock that could become issuable upon exercise of Series B Common Stock Warrants, 
 which we issued in a private placement transaction (the “March PIPE Financing”) pursuant to the Purchase Agreement, among us and the Purchasers.                                                                                           |

| Use of proceeds | We will not receive any proceeds from the sale of the shares of common stock covered by this prospectus. We may, however, receive up to approximately $37 million in aggregate gross proceeds from the exercise of the Pre-Funded Warrants and the Series A Common Warrants if such warrants are exercised for cash. We could, receive, up to approximately $55.5 million in aggregate gross proceeds from the exercise of the Series B 
 Common Warrants, but we do not expect such warrants to be exercised for cash. We expect to use any proceeds from any exercise of the Warrants for general corporate purposes. See the section titled “Use of Proceeds.”                                                                                                                                                                                                                 |

| Nasdaq Symbol | “PSTV” |

| Offering price | The selling stockholders will offer the shares of common stock offered by this prospectus at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. |

| Risk factors | Any investment in shares of common stock offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under the section entitled “Risk Factors” and elsewhere in this 
 prospectus.                                                                                                                                                                                                                        |

2

RISK FACTORS

An investment in our shares of common stock involves a high degree of risk. In addition to the risks and uncertainties discussed above under “Cautionary
Note Regarding Forward-Looking Statements,” you should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and all other information contained or
incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in any applicable prospectus supplement, before making an investment decision. Our
business, prospects, financial condition or operating results could decline due to any of these risks and, as a result,